For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

They provided evidence to guide treatment decisions for COPD patients. Study: Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease ...

.In December 2024:- AstraZeneca- A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect ...

COPD and asthma devices are crucial in the management and treatment of respiratory diseases, providing relief and improving the quality of life for patients. These devices range from inhalers to ...

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...

End-stage COPD is marked by severe shortness of breath, even when at rest. At this stage, medications typically don’t work as well as they may have in the past. Everyday tasks will leave you ...

Results The study cohort included 20 388 propensity score matched pairs of new users initiating single inhaler triple therapy. Patients who received budesonide-glycopyrrolate-formoterol had a 9% ...